Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Development of a New Structural Class of Broadly Acting HCV Non-Nucleoside Inhibitors Leading to the Discovery of MK-8876.

McComas CC, Palani A, Chang W, Holloway MK, Lesburg CA, Li P, Liverton N, Meinke PT, Olsen DB, Peng X, Soll RM, Ummat A, Wu J, Wu J, Zorn N, Ludmerer SW.

ChemMedChem. 2017 Sep 7;12(17):1436-1448. doi: 10.1002/cmdc.201700228. Epub 2017 Jul 25.

PMID:
28741898
2.

Thiazomycin, nocathiacin and analogs show strong activity against clinical strains of drug-resistant Mycobacterium tuberculosis.

Singh SB, Xu L, Meinke PT, Kurepina N, Kreiswirth BN, Olsen DB, Young K.

J Antibiot (Tokyo). 2017 May;70(5):671-674. doi: 10.1038/ja.2016.165. Epub 2017 Jan 18.

PMID:
28096545
3.

Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.

Tong L, Yu W, Coburn CA, Meinke PT, Nair AG, Dwyer MP, Chen L, Selyutin O, Rosenblum SB, Jiang Y, Fells J, Hu B, Zhong B, Soll RM, Liu R, Agrawal S, Xia E, Zhai Y, Kong R, Ingravallo P, Nomeir A, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5132-5137. doi: 10.1016/j.bmcl.2016.07.057. Epub 2016 Jul 25.

4.

Discovery of novel dihydrobenzofuran cyclopropane carboxylic acid based calcium sensing receptor antagonists for the treatment of osteoporosis.

Liang GB, Zhou C, Huo X, Wang H, Yang X, Huang S, Wang H, Wilkinson H, Luo L, Tang W, Sutton D, Li H, Zaller D, Meinke PT.

Bioorg Med Chem Lett. 2016 Aug 15;26(16):4077-80. doi: 10.1016/j.bmcl.2016.06.073. Epub 2016 Jun 29.

PMID:
27397499
5.

In Vitro and In Vivo Characterization of the Novel Oxabicyclooctane-Linked Bacterial Topoisomerase Inhibitor AM-8722, a Selective, Potent Inhibitor of Bacterial DNA Gyrase.

Tan CM, Gill CJ, Wu J, Toussaint N, Yin J, Tsuchiya T, Garlisi CG, Kaelin D, Meinke PT, Miesel L, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Oohata K, Takeuchi T, Shibue T, Takano H, Nishimura A, Fukuda Y, Singh SB.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4830-9. doi: 10.1128/AAC.00619-16. Print 2016 Aug.

6.

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.

Yu W, Coburn CA, Yang DY, Meinke PT, Wong M, Rosenblum SB, Chen KX, Njoroge GF, Chen L, Dwyer MP, Jiang Y, Nair AG, Selyutin O, Tong L, Zeng Q, Zhong B, Ji T, Hu B, Agrawal S, Xia E, Zhai Y, Liu R, Kong R, Ingravallo P, Asante-Appiah E, Nomeir A, Fells J, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3158-3162. doi: 10.1016/j.bmcl.2016.04.084. Epub 2016 Apr 30.

PMID:
27180013
7.

Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5).

Singh SB, Kaelin DE, Meinke PT, Wu J, Miesel L, Tan CM, Olsen DB, Lagrutta A, Fukuda H, Kishii R, Takei M, Takeuchi T, Takano H, Ohata K, Kurasaki H, Nishimura A, Shibata T, Fukuda Y.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3630-5. doi: 10.1016/j.bmcl.2015.06.061. Epub 2015 Jun 23.

PMID:
26152426
8.

Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6).

Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Liao Y, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Yajima M, Shibue T, Shibata T, Ohata K, Nishimura A, Fukuda Y.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3636-43. doi: 10.1016/j.bmcl.2015.06.057. Epub 2015 Jun 19.

PMID:
26141771
9.

Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3).

Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Gill C, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takeuchi T, Shibue T, Ohata K, Takano H, Ban S, Nishimura A, Fukuda Y.

Bioorg Med Chem Lett. 2015 Jun 15;25(12):2473-8. doi: 10.1016/j.bmcl.2015.04.063. Epub 2015 Apr 28.

PMID:
25978963
10.

Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4).

Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen DB, Lagrutta A, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Shibata T, Ohata K, Takano H, Kurasaki H, Takeuchi T, Nishimura A, Fukuda Y.

Bioorg Med Chem Lett. 2015 Jun 1;25(11):2409-15. doi: 10.1016/j.bmcl.2015.04.002. Epub 2015 Apr 7.

PMID:
25911300
11.

Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2).

Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Black T, Nargund R, Meinke PT, Olsen DB, Lagrutta A, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Sherer E, Joyce LA, Wei C, Peng X, Wang X, Fukuda H, Kishii R, Takei M, Takano H, Shibasaki M, Yajima M, Nishimura A, Shibata T, Fukuda Y.

Bioorg Med Chem Lett. 2015 May 1;25(9):1831-5. doi: 10.1016/j.bmcl.2015.03.044. Epub 2015 Mar 24.

PMID:
25851938
12.

Design, synthesis, structure-function relationship, bioconversion, and pharmacokinetic evaluation of ertapenem prodrugs.

Singh SB, Rindgen D, Bradley P, Suzuki T, Wang N, Wu H, Zhang B, Wang L, Ji C, Yu H, Soll RM, Olsen DB, Meinke PT, Nicoll-Griffith DA.

J Med Chem. 2014 Oct 23;57(20):8421-44. doi: 10.1021/jm500879a. Epub 2014 Oct 14.

PMID:
25265501
13.

Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents.

Singh SB, Kaelin DE, Wu J, Miesel L, Tan CM, Meinke PT, Olsen D, Lagrutta A, Bradley P, Lu J, Patel S, Rickert KW, Smith RF, Soisson S, Wei C, Fukuda H, Kishii R, Takei M, Fukuda Y.

ACS Med Chem Lett. 2014 Mar 12;5(5):609-14. doi: 10.1021/ml500069w. eCollection 2014 May 8.

14.

Design, synthesis, and evaluation of prodrugs of ertapenem.

Singh SB, Rindgen D, Bradley P, Cama L, Sun W, Hafey MJ, Suzuki T, Wang N, Wu H, Zhang B, Wang L, Ji C, Yu H, Soll R, Olsen DB, Meinke PT, Nicoll-Griffith DA.

ACS Med Chem Lett. 2013 Jul 3;4(8):715-9. doi: 10.1021/ml400092n. eCollection 2013 Aug 8.

15.

Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.

Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B, Huang Q, Kargman S, Kozlowski J, Liu R, McCauley JA, Nomeir AA, Soll RM, Vacca JP, Wang D, Wu H, Zhong B, Olsen DB, Ludmerer SW.

ChemMedChem. 2013 Dec;8(12):1930-40. doi: 10.1002/cmdc.201300343. Epub 2013 Oct 14.

PMID:
24127258
16.

Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs.

Xu L, Farthing AK, Dropinski JF, Meinke PT, McCallum C, Hickey E, Liu K.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):366-9. doi: 10.1016/j.bmcl.2012.10.065. Epub 2012 Oct 23.

PMID:
23164707
17.

Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.

Tan Y, Muise ES, Dai H, Raubertas R, Wong KK, Thompson GM, Wood HB, Meinke PT, Lum PY, Thompson JR, Berger JP.

Mol Pharmacol. 2012 Jul;82(1):68-79. doi: 10.1124/mol.111.076679. Epub 2012 Apr 10.

18.

Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

Liu W, Lau F, Liu K, Wood HB, Zhou G, Chen Y, Li Y, Akiyama TE, Castriota G, Einstein M, Wang C, McCann ME, Doebber TW, Wu M, Chang CH, McNamara L, McKeever B, Mosley RT, Berger JP, Meinke PT.

J Med Chem. 2011 Dec 22;54(24):8541-54. doi: 10.1021/jm201061j. Epub 2011 Nov 28.

PMID:
22070604
19.

Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3).

Coburn CA, Luo Y, Cui M, Wang J, Soll R, Dong J, Hu B, Lyon MA, Santarelli VP, Kraus RL, Gregan Y, Wang Y, Fox SV, Binns J, Doran SM, Reiss DR, Tannenbaum PL, Gotter AL, Meinke PT, Renger JJ.

ChemMedChem. 2012 Jan 2;7(1):123-33. doi: 10.1002/cmdc.201100351. Epub 2011 Sep 14.

PMID:
21916012
20.

Design of potent and selective GPR119 agonists for type II diabetes.

Szewczyk JW, Acton J, Adams AD, Chicchi G, Freeman S, Howard AD, Huang Y, Li C, Meinke PT, Mosely R, Murphy E, Samuel R, Santini C, Yang M, Zhang Y, Zhao K, Wood HB.

Bioorg Med Chem Lett. 2011 May 1;21(9):2665-9. doi: 10.1016/j.bmcl.2010.12.086. Epub 2010 Dec 22.

PMID:
21273063
21.

Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

Liu W, Liu K, Wood HB, McCann ME, Doebber TW, Chang CH, Akiyama TE, Einstein M, Berger JP, Meinke PT.

J Med Chem. 2009 Jul 23;52(14):4443-53. doi: 10.1021/jm900367w.

PMID:
19530681
22.

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.

Acton JJ 3rd, Akiyama TE, Chang CH, Colwell L, Debenham S, Doebber T, Einstein M, Liu K, McCann ME, Moller DE, Muise ES, Tan Y, Thompson JR, Wong KK, Wu M, Xu L, Meinke PT, Berger JP, Wood HB.

J Med Chem. 2009 Jul 9;52(13):3846-54. doi: 10.1021/jm900097m. Erratum in: J Med Chem. 2013 Nov 27;56(22):9368. Tan, Yugen [corrected to Tan, Yejun].

PMID:
19507861
23.

Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.

Xu L, Farthing AK, Dropinski JF, Meinke PT, McCallum C, Leavitt PS, Hickey EJ, Colwell L, Barrett J, Liu K.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3531-5. doi: 10.1016/j.bmcl.2009.04.144. Epub 2009 May 5.

PMID:
19447613
24.

Discovery of the development candidate N-tert-butyl nodulisporamide: a safe and efficacious once monthly oral agent for the control of fleas and ticks on companion animals.

Meinke PT, Colletti SL, Fisher MH, Wyvratt MJ, Shih TL, Ayer MB, Li C, Lim J, Ok D, Salva S, Warmke LM, Zakson M, Michael BF, Demontigny P, Ostlind DA, Fink D, Drag M, Schmatz DM, Shoop WL.

J Med Chem. 2009 Jun 11;52(11):3505-15. doi: 10.1021/jm801334v.

PMID:
19445514
25.

Highly functionalized 7-azaindoles as selective PPAR gamma modulators.

Debenham SD, Chan A, Lau FW, Liu W, Wood HB, Lemme K, Colwell L, Habulihaz B, Akiyama TE, Einstein M, Doebber TW, Sharma N, Wang CF, Wu M, Berger JP, Meinke PT.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4798-801. doi: 10.1016/j.bmcl.2008.07.103. Epub 2008 Jul 30.

PMID:
18701276
26.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036. Epub 2008 Feb 14.

PMID:
18346728
27.

Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).

Methot JL, Chakravarty PK, Chenard M, Close J, Cruz JC, Dahlberg WK, Fleming J, Hamblett CL, Hamill JE, Harrington P, Harsch A, Heidebrecht R, Hughes B, Jung J, Kenific CM, Kral AM, Meinke PT, Middleton RE, Ozerova N, Sloman DL, Stanton MG, Szewczak AA, Tyagarajan S, Witter DJ, Secrist JP, Miller TA.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):973-8. doi: 10.1016/j.bmcl.2007.12.031. Epub 2008 Jan 7.

PMID:
18182289
28.

The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.

Einstein M, Akiyama TE, Castriota GA, Wang CF, McKeever B, Mosley RT, Becker JW, Moller DE, Meinke PT, Wood HB, Berger JP.

Mol Pharmacol. 2008 Jan;73(1):62-74. Epub 2007 Oct 16.

29.

Conversion of nocathiacin I to nocathiacin acid by a mild and selective cleavage of dehydroalanine.

Xu L, Farthing AK, Shi YJ, Meinke PT, Liu K.

J Org Chem. 2007 Sep 14;72(19):7447-50. Epub 2007 Aug 18.

PMID:
17705543
30.

A series of novel, potent, and selective histone deacetylase inhibitors.

Jones P, Altamura S, Chakravarty PK, Cecchetti O, De Francesco R, Gallinari P, Ingenito R, Meinke PT, Petrocchi A, Rowley M, Scarpelli R, Serafini S, Steinkühler C.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5948-52. Epub 2006 Sep 20.

PMID:
16987657
31.

Design and synthesis of potent and subtype-selective PPARalpha agonists.

Desai RC, Metzger E, Santini C, Meinke PT, Heck JV, Berger JP, MacNaul KL, Cai TQ, Wright SD, Agrawal A, Moller DE, Sahoo SP.

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1673-8. Epub 2005 Dec 27.

PMID:
16384704
32.

Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.

Dropinski JF, Akiyama T, Einstein M, Habulihaz B, Doebber T, Berger JP, Meinke PT, Shi GQ.

Bioorg Med Chem Lett. 2005 Nov 15;15(22):5035-8.

PMID:
16153845
33.

Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.

Shi GQ, Dropinski JF, Zhang Y, Santini C, Sahoo SP, Berger JP, Macnaul KL, Zhou G, Agrawal A, Alvaro R, Cai TQ, Hernandez M, Wright SD, Moller DE, Heck JV, Meinke PT.

J Med Chem. 2005 Aug 25;48(17):5589-99.

PMID:
16107159
34.

Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain.

Liang J, Brochu RM, Cohen CJ, Dick IE, Felix JP, Fisher MH, Garcia ML, Kaczorowski GJ, Lyons KA, Meinke PT, Priest BT, Schmalhofer WA, Smith MM, Tarpley JW, Williams BS, Martin WJ, Parsons WH.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2943-7.

PMID:
15878274
35.

Selective PPARgamma modulators with improved pharmacological profiles.

Liu K, Black RM, Acton JJ 3rd, Mosley R, Debenham S, Abola R, Yang M, Tschirret-Guth R, Colwell L, Liu C, Wu M, Wang CF, MacNaul KL, McCann ME, Moller DE, Berger JP, Meinke PT, Jones AB, Wood HB.

Bioorg Med Chem Lett. 2005 May 16;15(10):2437-40.

PMID:
15863293
36.

PPARs: therapeutic targets for metabolic disease.

Berger JP, Akiyama TE, Meinke PT.

Trends Pharmacol Sci. 2005 May;26(5):244-51. Review.

PMID:
15860371
37.

Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain.

Shao PP, Ok D, Fisher MH, Garcia ML, Kaczorowski GJ, Li C, Lyons KA, Martin WJ, Meinke PT, Priest BT, Smith MM, Wyvratt MJ, Ye F, Parsons WH.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1901-7.

PMID:
15780630
38.

PPAR ligands: potential therapies for metabolic syndrome.

Akiyama TE, Meinke PT, Berger JP.

Curr Diab Rep. 2005 Feb;5(1):45-52. Review.

PMID:
15663917
39.

A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model.

Priest BT, Garcia ML, Middleton RE, Brochu RM, Clark S, Dai G, Dick IE, Felix JP, Liu CJ, Reiseter BS, Schmalhofer WA, Shao PP, Tang YS, Chou MZ, Kohler MG, Smith MM, Warren VA, Williams BS, Cohen CJ, Martin WJ, Meinke PT, Parsons WH, Wafford KA, Kaczorowski GJ.

Biochemistry. 2004 Aug 3;43(30):9866-76.

PMID:
15274641
40.

Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy.

Cosford ND, Meinke PT, Stauderman KA, Hess SD.

Curr Drug Targets CNS Neurol Disord. 2002 Feb;1(1):81-104. Review.

PMID:
12769636
41.

Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump.

Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD.

J Biol Chem. 2003 Mar 21;278(12):10214-20. Epub 2003 Jan 13.

42.

Nodulisporic acid side-chain modifications: access to the 2", 3", 4", and 6" registers.

Chakravarty PK, Shih TL, Colletti SL, Ayer MB, Snedden C, Kuo H, Tyagarajan S, Gregory L, Zakson-Aiken M, Shoop WL, Schmatz DM, Wyvratt M, Fisher MH, Meinke PT.

Bioorg Med Chem Lett. 2003 Jan 6;13(1):147-50.

PMID:
12467636
43.

Side-chain homologation of nodulisporic acid: synthesis of potent new dienyl derivatives.

Ok D, Li C, Shih TL, Salva S, Ayer MB, Colletti SL, Chakravarty PK, Wyvratt MJ, Fisher MH, Gregory L, Zakson-Aiken M, Shoop WL, Schmatz DM, Meinke PT.

Bioorg Med Chem Lett. 2002 Jul 8;12(13):1751-4.

PMID:
12067553
44.

Comparison of nodulisporic acid analogs in a Lucilia sericata in vitro assay and a Ctenocephalides felis membrane feeding system.

Felcetto T, Ondeyka J, Colletti SL, Meinke PT, Shoop WL.

J Parasitol. 2002 Apr;88(2):223-6.

PMID:
12053989
45.

Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity.

Yu J, Lo JL, Huang L, Zhao A, Metzger E, Adams A, Meinke PT, Wright SD, Cui J.

J Biol Chem. 2002 Aug 30;277(35):31441-7. Epub 2002 Jun 6.

46.

Nodulisporic acid: its chemistry and biology.

Meinke PT, Smith MM, Shoop WL.

Curr Top Med Chem. 2002 Jul;2(7):655-74. Review.

PMID:
12052184
47.

Ivermectin and nodulisporic acid receptors in Drosophila melanogaster contain both gamma-aminobutyric acid-gated Rdl and glutamate-gated GluCl alpha chloride channel subunits.

Ludmerer SW, Warren VA, Williams BS, Zheng Y, Hunt DC, Ayer MB, Wallace MA, Chaudhary AG, Egan MA, Meinke PT, Dean DC, Garcia ML, Cully DF, Smith MM.

Biochemistry. 2002 May 21;41(20):6548-60.

PMID:
12009920
48.

Synthesis of side chain truncated 3"-aldehyde, 3"-carboxylic acid, and 1"-aldehyde from nodulisporic acid A.

Chakravarty PK, Tyagarajan S, Shih TL, Salva S, Snedden C, Wyvratt MJ, Fisher MH, Meinke PT.

Org Lett. 2002 Apr 18;4(8):1291-4.

PMID:
11950345
49.

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.

Thompson JE, Cubbon RM, Cummings RT, Wicker LS, Frankshun R, Cunningham BR, Cameron PM, Meinke PT, Liverton N, Weng Y, DeMartino JA.

Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23.

PMID:
11934592
50.

Synthesis of nodulisporic acid 2' '-oxazoles and 2' '-thiazoles.

Berger R, Shoop WL, Pivnichny JV, Warmke LM, Zakson-Aiken M, Owens KA, deMontigny P, Schmatz DM, Wyvratt MJ, Fisher MH, Meinke PT, Colletti SL.

Org Lett. 2001 Nov 15;3(23):3715-8.

PMID:
11700120

Supplemental Content

Loading ...
Support Center